Oyster Point Pharma’s nasal spray for DED now covered by Express Scripts

Oyster Point Pharma announced Tuesday that its TYRVAYA (varenicline solution) nasal spray 0.03 mg has been placed on the Express Scripts National Preferred, Basic, and High Performance Formularies, effective over the weekend.

Approved by the FDA last October, TRYVAYA became commercially available at U.S. pharmacies and for home delivery the following month.

It is currently the first and only multi-dose nasal spray designed to treat the signs and symptoms of dry eye disease (DED).

The nasal spray is believed to be as a result of varenicline’s activity at heteromeric sub-type(s) of the nicotinic acetylcholine (nACh) receptor, where its binding produces agonist activity and activates the trigeminal parasympathetic pathway, thereby resulting in an increased basal tear film production to treat DED, according to the company.

“The addition of TYRVAYA nasal spray to Express Scripts’ formulary moves us forward with our plan to optimize coverage and ensure patients and eye care professionals have access to the first and only nasal spray approved for the signs and symptoms of dry eye disease,” said John Snisarenko, MBA, Oyster Point Pharma’s chief commercial officer, in a news release.

See more dry eye coverage